REGENERON PHARMACEUTICALS, INC. (REGN) Net margin 2016–2025
REGENERON PHARMACEUTICALS, INC. (REGN) net profit margin by fiscal year — reported net income divided by reported revenue.
31.4%FY2025 · since FY2016: 18.4% → 31.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 31.4% | +0.3 pp |
| FY2024 | 31.1% | +0.9 pp |
| FY2023 | 30.1% | -5.5 pp |
| FY2022 | 35.6% | -14.6 pp |
| FY2021 | 50.2% | +8.9 pp |
| FY2020 | 41.3% | +9.1 pp |
| FY2019 | 32.3% | -15.2 pp |
| FY2018 | 47.5% | +27.1 pp |
| FY2017 | 20.4% | +2.0 pp |
| FY2016 | 18.4% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More REGN financial trends
REGN RevenueREGN Net incomeREGN Gross profitREGN Gross marginREGN Operating incomeREGN Operating marginREGN Operating cash flowREGN Free cash flowREGN Capital expendituresREGN Return on equityREGN Stock buybacksREGN Dividends paidREGN Total assetsREGN Total liabilitiesREGN Shareholders’ equityREGN overview →